

SEND TO

Department of Pathology UMC Utrecht
Attn Molecular Pathology
Roomnumber H04.312
Heidelberglaan 100
3584 CX Utrecht
The Netherlands

Patient information

Name + initials:

Adress:

Date of birth:

Gender:

Citizen Service Number (BSN):

**Patient administration**

Tel +31 (0)88 7557615
Fax +31 (0)88 7569588
E-mail administratie-pathologie@umcutrecht.nl

Molecular Pathology

Tel +31 (0)88 7574252
E-mail pathology-moleculardiagnosics@umcutrecht.nl

PATHOLOGY UMC UTRECHT:

Requesting laboratory and/or physician

Name : Date :
Department (code) : External PA- and/or reference number :
Institution/country :

Material

H&E stained slide

FFPE block :

Fresh frozen* :

*Tick the box in case of fresh frozen material for PMC:

*Tick the box in case of fresh frozen material for PMC **and** blood for PMC (FFPE will follow):

DNA :

Other :

Slides** :

**In case of slides: for non-FISH applications: 10 unstained sections 4µm (coated slides)
for FISH applications: 6 unstained sections 4µm (coated slides)

By sending stained slides, the final report will be delayed by 1-3 days

REMARKS:

NGS

- BRCA 1/2 (somatic)
 CLL (chronic lymphatic leukemia)
 Colon
 Desmoid tumor
 TERT
 GIST
 Glioma
 Hematological diseases
 LPL (lymphoplasmacytic lymphoma)
 Melanoma
 Melanocytic lesions

 MPN (myeloproliferative neoplasms)
 Kidney panel (PMC)

 Thyroid carcinoma
 Tumor clonality

 TSO500
 Tumor first (ovarian cancer) incl. BRCA1/2
 Other
- TP53
BRAF/RAS
CTNNB1
Glioma panel
KIT/PDGFRA/BRAF
e.g. IDH1/IDH2/1p19q co-deletion
e.g. SF3B1/SRSF2/U2AF1/TET2/SXL1/EZH2
MYD88
BRAF/HRAS/NRAS/KIT
APC/BRAF/CTNNB1/GNA11/GNAQ/
HRAS/IDH1/KIT/NRAS/TERT
CALR/MPL/JAK2
TP53/WT1/WTX/FBXW7/SMARCB1/
SMARCA4
BRAF/RAS
TP53 NGS or SNParray depending on tumor type
- Indicate genes of interest at remarks

RT-PCR

- KIAA-BRAF duplication 7q34
 YWHAE-FAM22A/B t(10;17)
 EWSR1 FL1/ERG/WT1
 FGFR3-TACC3 duplication 4p16

Other molecular analyses

- Archer FusionPlex Lung
 Archer FusionPlex Melano Lung
 BRAF Idylla***** V600E/D/K/R/M
 HPV Allinity m (RvA: M208) High risk****
 HPV genotyping assay(RvA:M268) High risk + low risk****
 B-cel clonality
 T-cel clonality
 Tissue-identification

ddPCR

- BRAF p.(V600E)
 EGFR exon 19 deletions
 EGFR p.(L858R)
 EGFR resistance p.(T790M)
 MYD88 p.(L265P)
 TERT (C228T en C250T)

Arrays

- SNP array
 Methylation profiling

CNV profile , tumor clonality
Classification of CNS tumors
or sarcomas

Please turn over for IHC, FISH, MSI MLPA,
MLPA, DNA-isolation and Chimerism



Predictive IHC

- PD-L1 (lung)
 PD-L1 (bladder)
 PD-L1 (breast)
 Pan-NTRK
 ALK
 ROS1

Fluorescence In Situ Hybridisation

Soft tissue

- CHOP
 EWSR1
 FKHR (FOXO1)
 FUS
 MDM2
 SYT
Break-apart
Break-apart + fusion FLI1
Break-apart
Break-apart
Break-apart
Break-apart

Lymphoma

- BCL-2
 BCL6
 cMYC
 CCND1 (Cyclin-D1)
 MALT1
Break-apart
Break-apart
Break-apart + fusion IgH
Break-apart
Break-apart

Chromosomes

- Centromere X/Y/18
 Centromere 13/18/21

Other

- ALK
 BCOR
 cMET
 COL1A1-PDGFB
 ERBB2 (Her2neu)
 ETV6
 HMGA2
 MAML2
 MUM1 (IRF4)
 MYB
 N-MYC
 NRG1
 NTRK 1/2/3
 PLAG1
 PLAG1/CTNNB1
 RET
 ROS1
 TFE3
 USP6
 NTRK 1
 NTRK 2
 NTRK 3
 Research ISH
Break-apart
Break-apart
Amplification
Fusion
Amplification
Break-apart
Break-apart
Break-apart
Break-apart
Break-apart
Amplification
Break-apart
Break-apart
Break-apart
Break-apart
Fusion
Break-apart
Break-apart
Break-apart
Break-apart
Break-apart
Break-apart
Break-apart
Break-apart
Break-apart
Break-apart
Indicate gene of interest at remarks

MSI

- MSI Lynch syndrome colon (only tumor tissue, >20% tumor) using Idylla
 MSI Lynch syndrome tissues other than colon or colon with <20% tumor (tumor and normal tissue) using Bethesda markers
 MSI for therapeutic purposes (only tumor tissue) using MMR IHC
 MLH1 hypermethylation and BRAF V600E Mutation analysis using MLPA

DNA-isolation

- DNA-isolation tumor tissue
 DNA-isolation normal tissue
 DNA-isolation other, e.g. blood

MLPA

- MLPA 1p19q co-deletion
 MLPA FGFR
 MLPA Her2neu
 MLPA MDM2/CDK4
 MLPA Trisomy 13/18/21/X/Y
 MS-MLPA BRCA1 hypermethylation
 MS-MLPA MGMT promoter methylation

Chimerism

- Whole blood
 T-/non-T

* For lung applications: also send a distinctive staining, e.g. TTF1, together with your application
** If no mutations are found in KRAS and/or EGFR for adenocarcinoma/NSCLC, additional translocation analysis will be performed (according to agreement)
*** If no mutations are found in KRAS and/or FGFR1 for squamous cell carcinoma an additional ALK analysis will be performed
**** For all HPV applications:
Severe dysplasia/CIS/invasive: apply for HPV m Allinity
Low/moderate dysplasia/verrucous: apply for HPV genotyping assay
***** For BRAF Idylla please send a block or a 10µm tissue slide in a tube with a representative H&E staining for the appropriate tumor percentage (at least 20% is necessary)